Compare MMT & TARA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MMT | TARA |
|---|---|---|
| Founded | 1987 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 247.7M | 268.5M |
| IPO Year | N/A | 2014 |
| Metric | MMT | TARA |
|---|---|---|
| Price | $4.53 | $5.17 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $23.60 |
| AVG Volume (30 Days) | 108.3K | ★ 523.4K |
| Earning Date | 01-01-0001 | 05-01-2026 |
| Dividend Yield | ★ 8.58% | N/A |
| EPS Growth | N/A | ★ 38.25 |
| EPS | ★ 0.30 | N/A |
| Revenue | N/A | ★ $2,948,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $15.12 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.37 | $2.77 |
| 52 Week High | $4.87 | $7.82 |
| Indicator | MMT | TARA |
|---|---|---|
| Relative Strength Index (RSI) | 42.66 | 46.37 |
| Support Level | $4.37 | $4.92 |
| Resistance Level | $4.72 | $5.44 |
| Average True Range (ATR) | 0.06 | 0.25 |
| MACD | -0.01 | 0.04 |
| Stochastic Oscillator | 4.35 | 41.54 |
MFS Multimarket Income Trust is a diversified closed-end management investment company. Its investment objective is to seek high current income, but may also consider capital appreciation. The fund invests a majority of its net assets in fixed-income securities, corporate bonds of the U.S and foreign issuers, U.S Government securities, foreign government securities, mortgage-backed and other asset-backed securities of U.S and foreign issuers, and debt instruments of issuers located in emerging market countries. The portfolio of investments comprises of different sector investments such as aerospace, automotive, chemicals, electronics, and others.
Protara Therapeutics Inc is committed to identifying and advancing transformative therapies for people with cancer and rare diseases. The company discovers, develops and delivers breakthrough therapies to people who have limited treatment options. Its portfolio includes its program, TARA-002, being developed for the treatment of lymphatic malformations, and intravenous (IV) choline chloride, a phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease (IFALD).